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The presentation will discuss the status of the biotech-
nology sector in Brazil.
We see a lot of attention in the last months to the
Health Ministry effort to decrease the health trade defi-
cit by establishing technology transfer and production
agreements evolving international and local companies
and public institutions. The emergence of companies as
Orygen and Bionovis and the announced projects con-
ducted by Biomm and Recepta are part of this strategy.
On the other hand, we also see a complex scenario for
start-ups in the bio field. In fact, it is even more difficult
for entrepreneurs or researchers to start a company in
Brazil due to the lack of programs to support them.
On the second stage, start-ups have to deal with an
unbelievable regulatory environment where companies
have to wait two or more years to start operations. And
no financing: non-refundable resources are scarce at
FINEP, the brazilian innovation agency. It is also hard
for a start-up to find investors, as there are few funds
investing in life sciences projects. So, companies are
financed by a combination of research/scientific pro-
grams, state level programs and, in some cases, angel
investors.
Management is also a trouble for the start-ups. Only a
few have dedicated business teams, scientific interaction is
small and collaborations with local or international com-
panies are rare. Whether these are causes of consequences
of the financial situation has still to be determined.
Also, the environment for biotechnology has to be ana-
lyzed. We see a lack of crucial components in the product
development chain in the country, from pre-clinical labs,
translational centers to biologics manufacturing facilities.
There are not many professional business incubators and
technology parks too. And also, it is not easy to find
trained people in product development.
In the short term, the development of the bioindustry in
Brazil will depend on how these big projects will perform.
In case of success, they could create a positive cycle,
encouraging new projects and creating a positive legal and
regulatory environment. Will all the other companies have
to wait ? Or can we use different strategies together ?
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